The SGLT2 inhibitor empagliflozin reduces mortality in experimental pulmonary hypertension

被引：0
|
作者：
Chowdhury, B. [1 ]
Luu, V. Z. [1 ]
Luu, A. Z. [1 ]
Kabir, M. G. [1 ]
Pan, Y. [1 ]
Teoh, H. [1 ]
Quan, A. [1 ]
Mazer, C. D. [2 ]
Verma, S. [1 ]
机构：
[1] St Michaels Hosp, Cardiac Surg, Toronto, ON, Canada
[2] St Michaels Hosp, Anesthesia, Toronto, ON, Canada
来源：
EUROPEAN HEART JOURNAL | 2019年 / 40卷
基金：
加拿大健康研究院;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
56
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [21] Influence of the SGLT2 inhibitor empagliflozin on post myocardial infarction rat hearts
    Damatto, F. C.
    Paschoareli, G. L.
    Rosa, C. M.
    Gomes, M. J.
    Pagan, L. U.
    Damatto, R. L.
    Rodrigues, E. A.
    Pontes, T. H.
    Reyes, D. R. A.
    Cezar, M. D. M.
    Oliveira, L. R. S.
    Zornoff, L. A. M.
    Rego, A. B. G. C.
    Okoshi, M. P.
    Okoshi, K.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1115 - 1115
  • [22] The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
    Chu, Chang
    Lu, Yong-Ping
    Yin, Lianghong
    Hocher, Berthold
    KIDNEY & BLOOD PRESSURE RESEARCH, 2019, 44 (02): : 149 - 157
  • [23] Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
    Heimke, Marvin
    Lenz, Florian
    Rickert, Uta
    Lucius, Ralph
    Cossais, Francois
    CELLS, 2022, 11 (19)
  • [24] EFFECTS OF THE SGLT2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE
    Kolwelter, Julie
    Bosch, Agnes
    Jung, Susanne
    Linz, Peter
    Kannenkeril, Dennis
    Nagel, Armin M.
    Ott, Christian
    Bramlage, Peter
    Uder, Michael
    Achenbach, Stephan
    Schmieder, Roland
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1806 - 1806
  • [25] Effect of Gemfibrozil, Rifampicin, or Probenecid on the Pharmacokinetics of the SGLT2 Inhibitor Empagliflozin in Healthy Volunteers
    Macha, Sreeraj
    Koenen, Ruediger
    Sennewald, Regina
    Schoene, Katja
    Hummel, Noemi
    Riedmaier, Stephan
    Woerle, Hans J.
    Salsali, Afshin
    Broedl, Uli C.
    CLINICAL THERAPEUTICS, 2014, 36 (02) : 280 - 290
  • [26] SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
    Vallon, Volker
    Gerasimova, Maria
    Rose, Michael A.
    Masuda, Takahiro
    Satriano, Joseph
    Mayoux, Eric
    Koepsell, Hermann
    Thomson, Scott C.
    Rieg, Timo
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2014, 306 (02) : F194 - F204
  • [27] The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
    Janet B. McGill
    Diabetes Therapy, 2014, 5 : 43 - 63
  • [28] The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
    McGill, Janet B.
    DIABETES THERAPY, 2014, 5 (01) : 43 - 63
  • [29] The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy
    Chen, Hongping
    Teng, Da
    Xu, Bowen
    Wang, Chunxiao
    Wang, Hua
    Jia, Wenjuan
    Gong, Lei
    Dong, Haibin
    Zhong, Lin
    Yang, Jun
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2023, 16 (05) : 999 - 1009
  • [30] The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy
    Hongping Chen
    Da Teng
    Bowen Xu
    Chunxiao Wang
    Hua Wang
    Wenjuan Jia
    Lei Gong
    Haibin Dong
    Lin Zhong
    Jun Yang
    Journal of Cardiovascular Translational Research, 2023, 16 : 999 - 1009
12345